Search

Zentalis Pharmaceuticals Inc

Nyitva

3.79 -5.49

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.86

Maximum

4.07

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+119.11% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

47M

378M

Előző nyitás

9.28

Előző zárás

3.79

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 8. 23:56 UTC

Compass Minerals International Inc shares are lower in after-market hours, with no specific news identified. Broader market expectations for an interest rate hike persist.

2026. szept. 8. 23:56 UTC

Pacific Biosciences of California Inc. shares are higher in after-market trading, despite fluctuations, and remain above their 20-day moving average.

2026. szept. 8. 23:56 UTC

NextDecade Corp shares gained slightly in after-market trading. The stock remains above its 20-day moving average amid broader economic influences.

2026. szept. 8. 23:56 UTC

Arrow Financial Corp shares are lower in after-market hours with no specific news identified. The stock has recovered from an initial decline.

2026. szept. 8. 23:56 UTC

Qualys Inc shares are lower in after-market trading amid broader market weakness. The stock has declined for three consecutive sessions.

2026. szept. 8. 23:56 UTC

Correlated Moves

Illinois Tool Works Inc shares are lower in after-market trading, reflecting broader industrial sector trends and influenced by declines in Lincoln Electric Holdings Inc.

2026. szept. 8. 23:56 UTC

PPL Corp shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report that raised interest rate hike expectations.

2026. szept. 8. 23:56 UTC

Correlated Moves

Samsara Inc shares are lower in after-market hours, influenced by ServiceTitan Inc's significant drop and broader market concerns over potential interest rate hikes.

2026. szept. 8. 23:56 UTC

News

Korn Ferry's Board declared a quarterly cash dividend of $0.55 per share, payable October 15. Shares traded roughly flat in after-market hours.

2026. szept. 8. 23:56 UTC

Mastercraft Boat Holdings Inc. shares were roughly flat in after-market hours, reflecting minimal price movement amid ongoing performance challenges.

2026. szept. 8. 23:56 UTC

Comcast Corp shares are lower in after-market trading, following a session low. Recent economic data has influenced market expectations for potential interest rate hikes.

2026. szept. 8. 23:56 UTC

Brown & Brown Inc shares are lower in after-market hours, reflecting broader market concerns over a potential interest rate hike following a strong jobs report.

2026. szept. 8. 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

2026. szept. 8. 23:56 UTC

Social Media
News

Chevron Corp shares are higher in after-market hours following a report on declining OECD strategic petroleum reserves, which may impact oil prices and benefit the company.

2026. szept. 8. 23:52 UTC

Ovid Therapeutics Inc is higher in after-market trading, reflecting positive momentum since Tuesday's close and positioning above its 20-day moving average.

2026. szept. 8. 23:52 UTC

Cardinal Health Inc shares are lower in after-market hours, with volatility noted despite no specific company news or developments influencing the decline.

2026. szept. 8. 23:51 UTC

CVR Energy Inc shares are higher in after-market trading, recovering from earlier volatility. Rising crude oil prices may be influencing market dynamics.

2026. szept. 8. 23:51 UTC

Harley-Davidson Inc shares are higher in after-market trading, reflecting volatility amid rising crude oil prices and inflation concerns following a strong jobs report.

2026. szept. 8. 23:51 UTC

Huron Consulting Group Inc shares are lower in after-market trading, retracing from an earlier session high and remaining below the 20-day moving average.

2026. szept. 8. 23:51 UTC

Range Resources Corp shares are higher in after-market trading, buoyed by rising crude oil prices nearing $99 per barrel and a strong jobs report.

2026. szept. 8. 23:51 UTC

Gold Resource Corp shares are lower in after-market hours amid rising crude oil prices and inflation concerns ahead of the Federal Reserve meeting.

2026. szept. 8. 23:51 UTC

Brazil's Retail Sales MoM report on September 15, 2026, expected to reveal consumer spending trends and impact economic growth outlook.

2026. szept. 8. 23:51 UTC

South Korea's unemployment rate drops to 2.7% in August, signaling strong job growth and positive investor sentiment amidst global economic uncertainties.

2026. szept. 8. 23:51 UTC

Japan's July Machinery Orders Expected to Reflect Positive Capital Spending Trends Amidst Economic Recovery and Investor Optimism

2026. szept. 8. 23:51 UTC

Japan's Trade Balance Data Release on September 15, 2026: Market Braces for Persistent Deficits Amid Weak Yen and Geopolitical Tensions.

2026. szept. 8. 23:51 UTC

Japan's upcoming exports data release on September 15, 2026, is anticipated to reflect continued reliance on high-tech products amid positive economic indicators and rising real wages, despite global market uncertainties.

2026. szept. 8. 23:51 UTC

Ambarella Inc. showed unusual strength in after-market trading, advancing despite rising crude oil prices and inflation concerns. No specific news was identified for the move.

2026. szept. 8. 23:51 UTC

ETSY Inc. shares are higher in after-market trading, despite remaining below the 20-day moving average and near the lower end of the one-month range.

2026. szept. 8. 23:51 UTC

Shares of United Airlines Holdings Inc. are higher in after-market trading, though they remain below the 20-day moving average and near the one-month range low.

2026. szept. 8. 23:51 UTC

Illumina Inc shares are higher in after-market trading, showing notable activity and positioning above the 20-day moving average amid a lack of specific news.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

119.11% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  119.11%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat